articleTop 1% cited

Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Diseases of the Colon & Rectum · 2011 · Vol. 54(12) · pp. 1552–1559

Stephen R. Gorfine✉(Mount Sinai Medical Center)Erol Onel(Pacira (United States))Gary Patou(Pacira (United States))Zoran Krivokapić(Center for Health, Exercise and Sport Sciences)

View via DOI Publisher page

Abstract

Bupivacaine extended-release demonstrated a statistically significant reduction in pain through 72 hours, decreased opioid requirements, delayed time to first opioid use, and improved patient satisfaction compared with placebo after hemorrhoidectomy.

Anesthesia and Pain Management Anorectal Disease Treatments and Outcomes Pain Management and Opioid UseMedicineBupivacainePlaceboAnesthesiaOpioidRandomized controlled trialLocal anestheticSurgeryAnalgesicPlacebo-controlled study

MeSH terms

AdolescentAdultAgedAged, 80 and overAnesthetics, LocalBupivacaineDelayed-Action PreparationsDouble-Blind MethodFemaleHemorrhoidsHumansLiposomesMaleMiddle AgedPain Measurement

Citations

340

FWCI

14.44

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids